Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Research

Difference in the relative biological effectiveness and DNA damage repair processes in response to proton beam therapy according to the positions of the spread out Bragg peak

Authors: Hidehiro Hojo, Takeshi Dohmae, Kenji Hotta, Ryosuke Kohno, Atsushi Motegi, Atsushi Yagishita, Hideki Makinoshima, Katsuya Tsuchihara, Tetsuo Akimoto

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Background

Cellular responses to proton beam irradiation are not yet clearly understood, especially differences in the relative biological effectiveness (RBE) of high-energy proton beams depending on the position on the Spread-Out Bragg Peak (SOBP). Towards this end, we investigated the differences in the biological effect of a high-energy proton beam on the target cells placed at different positions on the SOBP, using two human esophageal cancer cell lines with differing radiosensitivities.

Methods

Two human esophageal cancer cell lines (OE21, KYSE450) with different radiosensitivities were irradiated with a 235-MeV proton beam at 4 different positions on the SOBP (position #1: At entry; position #2: At the proximal end of the SOBP; position #3: Center of the SOBP; position #4: At the distal end of the SOBP), and the cell survivals were assessed by the clonogenic assay. The RBE10 for each position of the target cell lines on the SOBP was determined based on the results of the cell survival assay conducted after photon beam irradiation. In addition, the number of DNA double-strand breaks was estimated by quantitating the number of phospho-histone H2AX (γH2AX) foci formed in the nuclei by immunofluorescence analysis.

Results

In regard to differences in the RBE of a proton beam according to the position on the SOBP, the RBE value tended to increase as the position on the SOBP moved distally. Comparison of the residual number of γH2AX foci at the end 24 h after the irradiation revealed, for both cell lines, a higher number of foci in the cells irradiated at the distal end of the SOPB than in those irradiated at the proximal end or center of the SOBP.

Conclusions

The results of this study demonstrate that the RBE of a high-energy proton beam and the cellular responses, including the DNA damage repair processes, to high-energy proton beam irradiation, differ according to the position on the SOBP, irrespective of the radiosensitivity levels of the cell lines.
Appendix
Available only for authorised users
Literature
1.
Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JD. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011;117:4707–13.CrossRefPubMedPubMedCentral
2.
Lin SH, Komaki R, Liao Z, Wei C, Myles B, Guo X, Palmer M, Mohan R, Swisher SG, Hofstetter WL, et al. Proton beam therapy and concurrent chemotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;83:e345–51.CrossRefPubMedPubMedCentral
3.
Oshiro Y, Mizumoto M, Okumura T, Hashimoto T, Fukumitsu N, Ohkawa A, Kanemoto A, Hashii H, Ohno T, Sakae T, et al. Results of proton beam therapy without concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2012;7:370–5.CrossRefPubMed
4.
Oshiro Y, Okumura T, Kurishima K, Homma S, Mizumoto M, Ishikawa H, Onizuka M, Sakai M, Goto Y, Hizawa N, et al. High dose concurrent chemo-proton therapy for Stage III NSCLC: preliminary results of a Phase II study. J Radiat Res. 2014;55:959–65.CrossRefPubMedPubMedCentral
5.
Takada A, Nakamura T, Takayama K, Makita C, Suzuki M, Azami Y, Kato T, Tsukiyama I, Hareyama M, Kikuchi Y, et al. Preliminary treatment results of proton beam therapy with chemoradiotherapy for stage I-III esophageal cancer. Cancer Med. 2016;5:506–15.CrossRefPubMedPubMedCentral
6.
Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiother Oncol. 2016;118:286–92.CrossRefPubMedPubMedCentral
7.
Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. Phys Med Biol. 2014;59:R419–72.CrossRefPubMed
8.
Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, Suit HD. Relative biological effectiveness (RBE) values for proton beam therapy. Int J Radiat Oncol Biol Phys. 2002;53:407–21.CrossRefPubMed
9.
Tommasino F, Durante M. Proton radiobiology. Cancers (Basel). 2015;7:353–81.CrossRef
10.
Petrovic I, Ristic-Fira A, Todorovic D, Koricanac L, Valastro L, Cirrone P, Cuttone G. Response of a radioresistant human melanoma cell line along the proton spread-out Bragg peak. Int J Radiat Biol. 2010;86:742–51.CrossRefPubMed
11.
Chaudhary P, Marshall TI, Perozziello FM, Manti L, Currell FJ, Hanton F, McMahon SJ, Kavanagh JN, Cirrone GA, Romano F, et al. Relative biological effectiveness variation along monoenergetic and modulated Bragg peaks of a 62-MeV therapeutic proton beam: a preclinical assessment. Int J Radiat Oncol Biol Phys. 2014;90:27–35.CrossRefPubMed
12.
Britten RA, Nazaryan V, Davis LK, Klein SB, Nichiporov D, Mendonca MS, Wolanski M, Nie X, George J, Keppel C. Variations in the RBE for cell killing along the depth-dose profile of a modulated proton therapy beam. Radiat Res. 2013;179:21–8.CrossRefPubMed
13.
Calugaru V, Nauraye C, Noel G, Giocanti N, Favaudon V, Megnin-Chanet F. Radiobiological characterization of two therapeutic proton beams with different initial energy spectra used at the Institut Curie Proton Therapy Center in Orsay. Int J Radiat Oncol Biol Phys. 2011;81:1136–43.CrossRefPubMed
14.
Iwata H, Ogino H, Hashimoto S, Yamada M, Shibata H, Yasui K, Toshito T, Omachi C, Tatekawa K, Manabe Y, et al. Spot scanning and passive scattering proton therapy: relative biological effectiveness and oxygen enhancement ratio in cultured cells. Int J Radiat Oncol Biol Phys. 2016;95:95–102.CrossRefPubMed
15.
Maeda K, Yasui H, Yamamori T, Matsuura T, Takao S, Suzuki M, Matsuda A, Inanami O, Shirato H. A nucleoside anticancer drug, 1-(3-C-Ethynyl-beta-D-Ribo-Pentofuranosyl)cytosine, induces depth-dependent enhancement of tumor cell death in Spread-Out Bragg Peak (SOBP) of proton beam. PLoS One. 2016;11:e0166848.CrossRefPubMedPubMedCentral
16.
Matsumoto Y, Matsuura T, Wada M, Egashira Y, Nishio T, Furusawa Y. Enhanced radiobiological effects at the distal end of a clinical proton beam: in vitro study. J Radiat Res. 2014;55:816–22.CrossRefPubMedPubMedCentral
17.
Wouters BG, Skarsgard LD, Gerweck LE, Carabe-Fernandez A, Wong M, Durand RE, Nielson D, Bussiere MR, Wagner M, Biggs P, et al. Radiobiological intercomparison of the 160 MeV and 230 MeV proton therapy beams at the Harvard Cyclotron Laboratory and at Massachusetts General Hospital. Radiat Res. 2015;183:174–87.CrossRefPubMed
18.
Olive PL. Retention of gammaH2AX foci as an indication of lethal DNA damage. Radiother Oncol. 2011;101:18–23.CrossRefPubMed
19.
Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, Weichselbaum RR. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004;279:2273–80.CrossRefPubMed
20.
Chaudhary P, Marshall TI, Currell FJ, Kacperek A, Schettino G, Prise KM. Variations in the processing of DNA double-strand breaks along 60-MeV therapeutic proton beams. Int J Radiat Oncol Biol Phys. 2016;95:86–94.CrossRefPubMedPubMedCentral
21.
Wilkens JJ, Oelfke U. Analytical linear energy transfer calculations for proton therapy. Med Phys. 2003;30:806.CrossRefPubMed
22.
Okamoto H, Kanai T, Kase Y, Matsumoto Y, Furusawa Y, Fujita Y, Saitoh H, Itami J, Kohno T. Relation between lineal energy distribution and relative biological effectiveness for photon beams according to the microdosimetric kinetic model. J Radiat Res. 2011;52:75–81.CrossRefPubMed
23.
Kanemoto A, Hirayama R, Moritake T, Furusawa Y, Sun L, Sakae T, Kuno A, Terunuma T, Yasuoka K, Mori Y, et al. RBE and OER within the spread-out Bragg peak for proton beam therapy: in vitro study at the Proton Medical Research Center at the University of Tsukuba. J Radiat Res. 2014;55:1028–32.CrossRefPubMedPubMedCentral
24.
Calugaru V, Nauraye C, Cordelieres FP, Biard D, De Marzi L, Hall J, Favaudon V, Megnin-Chanet F. Involvement of the Artemis protein in the relative biological efficiency observed with the 76-MeV proton beam used at the Institut Curie Proton Therapy Center in Orsay. Int J Radiat Oncol Biol Phys. 2014;90:36–43.CrossRefPubMed
25.
Paganetti H, Olko P, Kobus H, Becker R, Schmitz T, Waligorski MP, Filges D, Muller-Gartner HW. Calculation of relative biological effectiveness for proton beams using biological weighting functions. Int J Radiat Oncol Biol Phys. 1997;37:719–29.CrossRefPubMed
26.
Ivashkevich A, Redon CE, Nakamura AJ, Martin RF, Martin OA. Use of the gamma-H2AX assay to monitor DNA damage and repair in translational cancer research. Cancer Lett. 2012;327:123–33.CrossRefPubMed
27.
Rothkamm K, Horn S. gamma-H2AX as protein biomarker for radiation exposure. Ann Ist Super Sanita. 2009;45:265–71.PubMed
28.
Fontana AO, Augsburger MA, Grosse N, Guckenberger M, Lomax AJ, Sartori AA, Pruschy MN. Differential DNA repair pathway choice in cancer cells after proton- and photon-irradiation. Radiother Oncol. 2015;116:374–80.CrossRefPubMed
29.
Lobrich M, Shibata A, Beucher A, Fisher A, Ensminger M, Goodarzi AA, Barton O, Jeggo PA. gammaH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization. Cell Cycle. 2010;9:662–9.CrossRefPubMed
30.
Bracalente C, Ibanez IL, Molinari B, Palmieri M, Kreiner A, Valda A, Davidson J, Duran H. Induction and persistence of large gammaH2AX foci by high linear energy transfer radiation in DNA-dependent protein kinase-deficient cells. Int J Radiat Oncol Biol Phys. 2013;87:785–94.CrossRefPubMed
31.
Antonelli F, Campa A, Esposito G, Giardullo P, Belli M, Dini V, Meschini S, Simone G, Sorrentino E, Gerardi S, et al. Induction and repair of DNA DSB as revealed by H2AX phosphorylation foci in human fibroblasts exposed to low- and high-LET radiation: relationship with early and delayed reproductive cell death. Radiat Res. 2015;183:417–31.CrossRefPubMed
Metadata
Title
Difference in the relative biological effectiveness and DNA damage repair processes in response to proton beam therapy according to the positions of the spread out Bragg peak
Authors
Hidehiro Hojo
Takeshi Dohmae
Kenji Hotta
Ryosuke Kohno
Atsushi Motegi
Atsushi Yagishita
Hideki Makinoshima
Katsuya Tsuchihara
Tetsuo Akimoto
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0849-1

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue

Research

Intentional avoidance of the esophagus using intensity modulated radiation therapy to reduce dysphagia after palliative thoracic radiation

Research

Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system

Research

Comparison of photon volumetric modulated arc therapy, intensity-modulated proton therapy, and intensity-modulated carbon ion therapy for delivery of hypo-fractionated thoracic radiotherapy

Research

Tumor motion changes in stereotactic body radiotherapy for liver tumors: an evaluation based on four-dimensional cone-beam computed tomography and fiducial markers

Research

Idelalisib may have the potential to increase radiotherapy side effects

Study protocol

“HEATPAC” - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer